Drug details:
Molecular formula: C₃₀H₂₁BrO₄

Standard name: 3-[3-[4-(4-bromophenyl)phenyl]-3-oxo-1-phenylpropyl]-4-hydroxychromen-2-one

Synonyms:

EINECS 249-106-0 3-[3-[4-(4-bromophenyl)phenyl]-3-oxo-1-phenylpropyl]-4-hydroxychromen-2-one 3-(3-(4'-Bromo-[1,1'-biphenyl]-4-yl)-3-oxo-1-phenylpropyl)-4-hydroxy-2H-chromen-2-one 3-(3-{4'-bromo-[1,1'-biphenyl]-4-yl}-3-oxo-1-phenylpropyl)-4-hydroxy-2H-chromen-2-one 3-[3-(4'-BROMO[1,1'-BIPHENYL]-4-YL)-3-OXO-1-PHENYLPROPYL]-4-HYDROXY-2-BENZOPYRONE 3-[3-(4'-bromobiphenyl-4-yl)-3-oxo-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one 3-(3-(4-Bromo(1,1-biphenyl)-4-yl)-3-oxo-1-phenylpropyl)-4-hydroxy-2-benzopyrone 3-{3-[4'-bromo(1,1'-biphenyl)-4-yl]-3-oxo-1-phenylpropyl}-4-hydroxy-2-benzopyrone Bromadiolone-Ketone, M2 ......

Curated SMILES: O=C(CC(C1=CC=CC=C1)C1=C(O)C2=C(C=CC=C2)OC1=O)C1=CC=C(C2=CC=C(Br)C=C2)C=C1

Evidence for compound's anti-virulence activity:

Brucella
Related VF: VirB type IV secretion system
Target: VirB8
Drug effect: Inhibits T4SS by targeting an essential assembly protein VirB8.
Max phase: Preclinical (in vivo)
Publication:
Paschos A, et al., 2011. An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation. Infect Immun 79(3):1033-43.